213 related articles for article (PubMed ID: 31400267)
1. Pharmacology of Ivabradine and the Effect on Chronic Heart Failure.
Zhou Y; Wang J; Meng Z; Zhou S; Peng J; Chen S; Wang Q; Sun K
Curr Top Med Chem; 2019; 19(21):1878-1901. PubMed ID: 31400267
[TBL] [Abstract][Full Text] [Related]
2. Ivabradine for the Treatment of Cardiovascular Diseases.
Ide T; Ohtani K; Higo T; Tanaka M; Kawasaki Y; Tsutsui H
Circ J; 2019 Jan; 83(2):252-260. PubMed ID: 30606942
[TBL] [Abstract][Full Text] [Related]
3. Ivabradine: Heart Failure and Beyond.
Chaudhary R; Garg J; Krishnamoorthy P; Shah N; Lanier G; Martinez MW; Freudenberger R
J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):335-43. PubMed ID: 26721645
[TBL] [Abstract][Full Text] [Related]
4. Selective pharmacological inhibition of the pacemaker channel isoforms (HCN1-4) as new possible therapeutical targets.
Koncz I; Szél T; Jaeger K; Baczkó I; Cerbai E; Romanelli MN; Gy Papp J; Varró A
Curr Med Chem; 2011; 18(24):3662-74. PubMed ID: 21774761
[TBL] [Abstract][Full Text] [Related]
5. Ivabradine: a new frontier in the treatment of stable coronary artery disease and chronic heart failure.
Gammone MA; Riccioni G; D'Orazio N
Clin Ter; 2020; 171(5):e449-e453. PubMed ID: 32901791
[TBL] [Abstract][Full Text] [Related]
6. Role of the Funny Current Inhibitor Ivabradine in Cardiac Pharmacotherapy: A Systematic Review.
Petite SE; Bishop BM; Mauro VF
Am J Ther; 2018; 25(2):e247-e266. PubMed ID: 26910057
[TBL] [Abstract][Full Text] [Related]
7. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure.
Pei H; Miao W; Xie WZ; Wang W; Zhao D; Su GH; Zhao Z
Int Heart J; 2019 Jul; 60(4):899-909. PubMed ID: 31308326
[TBL] [Abstract][Full Text] [Related]
8. Effect of ivabradine on cardiac arrhythmias: Antiarrhythmic or proarrhythmic?
Marciszek M; Paterek A; Oknińska M; Zambrowska Z; Mackiewicz U; Mączewski M
Heart Rhythm; 2021 Jul; 18(7):1230-1238. PubMed ID: 33737235
[TBL] [Abstract][Full Text] [Related]
9. Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.
Jirak P; Fejzic D; Paar V; Wernly B; Pistulli R; Rohm I; Jung C; Hoppe UC; Schulze PC; Lichtenauer M; Yilmaz A; Kretzschmar D
Acta Pharmacol Sin; 2018 Jul; 39(7):1189-1196. PubMed ID: 29239349
[TBL] [Abstract][Full Text] [Related]
10. Hyperpolarization-activated cyclic nucleotide-gated channel inhibitor in myocardial infarction: Potential benefits beyond heart rate modulation.
Sripusanapan A; Yanpiset P; Sriwichaiin S; Siri-Angkul N; Chattipakorn SC; Chattipakorn N
Acta Physiol (Oxf); 2024 Mar; 240(3):e14085. PubMed ID: 38230890
[TBL] [Abstract][Full Text] [Related]
11. Review: HCN Channels in the Heart.
Depuydt AS; Peigneur S; Tytgat J
Curr Cardiol Rev; 2022; 18(4):e040222200836. PubMed ID: 35125083
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the role of ivabradine in acute decompensated heart failure: A systematic review and meta-analysis.
Ashraf S; Khalaf AKS; Fatima L; Hashim HT; Irfan H; Ashfaq H; Khan MA; Zahid A; Akram U; Goyal A
Curr Probl Cardiol; 2024 Aug; 49(8):102604. PubMed ID: 38729277
[TBL] [Abstract][Full Text] [Related]
13. Ivabradine: A Unique and Intriguing Medication for Treating Cardiovascular Disease.
Nawarskas JJ; Bowman BN; Anderson JR
Cardiol Rev; 2015; 23(4):201-11. PubMed ID: 25839989
[TBL] [Abstract][Full Text] [Related]
14. Ivabradine in Management of Heart Failure: a Critical Appraisal.
Orasanu G; Al-Kindi SG; Oliveira GH
Curr Heart Fail Rep; 2016 Feb; 13(1):60-9. PubMed ID: 26797824
[TBL] [Abstract][Full Text] [Related]
15. Novel drugs for heart rate control in heart failure.
Bielecka-Dabrowa A; von Haehling S; Rysz J; Banach M
Heart Fail Rev; 2018 Jul; 23(4):517-525. PubMed ID: 29594814
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Profile of the Bradycardic Agent Ivabradine on Human Cardiac Ion Channels.
Haechl N; Ebner J; Hilber K; Todt H; Koenig X
Cell Physiol Biochem; 2019; 53(1):36-48. PubMed ID: 31169990
[TBL] [Abstract][Full Text] [Related]
17. HCN Channel as Therapeutic Targets for Heart Failure and Pain.
Cao Y; Pang J; Zhou P
Curr Top Med Chem; 2016; 16(16):1855-61. PubMed ID: 26667117
[TBL] [Abstract][Full Text] [Related]
18. Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine.
Elder DH; Mohan M; Cochrane L; Charles H; Lang CC
Cardiovasc Ther; 2015 Jun; 33(3):104-8. PubMed ID: 25809454
[TBL] [Abstract][Full Text] [Related]
19. Does Ivabradine Decrease Cardiovascular Deaths in Heart Failure Patients?
Marciniak TA; Atar D; Serebruany V
Am J Med; 2020 Mar; 133(3):347-351. PubMed ID: 31442391
[TBL] [Abstract][Full Text] [Related]
20. Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
Sallam M; Al-Saadi T; Alshekaili L; Al-Zakwani I
Curr Vasc Pharmacol; 2016; 14(5):481-486. PubMed ID: 27145825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
